GlassScriptPhysician profile
Joseph J Renzi
NPI 1043255003
$23,875.96
in general payments reported to CMS, 2019-2025
73 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,271 · 2020: $2,893 · 2021: $3,261 · 2022: $3,145 · 2023: $3,158 · 2024: $3,515 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,283 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,283.05 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,629.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,603.06 | 2019-2025 | |
| Novo Nordisk INC | $2,075.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,027.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,918.97 | 2019-2025 | Relistor, Xifaxan |
| Lilly USA, LLC | $872.46 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $764.26 | 2019-2023 | Xarelto |
| Pfizer INC. | $724.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $695.36 | 2019-2025 | Trintellix, Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.98 | 2019-2025 | Synjardy, Jardiance, Stiolto Respimat |
| Daiichi Sankyo INC. | $630.36 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $596.81 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $577.76 | 2019-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $516.55 | 2019-2024 | |
| Indivior INC. | $431.66 | 2019-2025 | Sublocade |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Renzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.